New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
05:11 EDTMDCOThe Medicines Co. Orbactiv approved by FDA
The Medicines Company announced that the FDA has approved Orbactiv for injection for the treatment of adults with acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus aureus. Orbactiv is the first and only antibiotic approved by FDA to treat ABSSSIs with a single, once-only administration. Once fully infused over three hours, the Orbactiv treatment regimen is complete for patients with skin infections caused by susceptible Gram-positive pathogens.
News For MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2015
08:30 EDTMDCOBioNJ to hold a summit
Subscribe for More Information
October 6, 2015
17:16 EDTMDCOThe Medicines Co., SymBio Pharmaceuticals enter strategic partnership in Japan
Subscribe for More Information
October 5, 2015
07:31 EDTMDCOThe Medicines Co. ALN-PCSsc 'a potential game changer,' says RBC Capital
After examining surveys and speaking with experts, RBC Capital says that the uptake of The Medicines Co's ALN-PCSsc treatment has been strong among anti-PCSK9 patients, reaching 20%-30%. The firm estimates that the company could conservatively generate $9B-$18B in revenue from the drug. It believes that the product is "a potential game changer and valuation driver" for the company. RBC keeps a $46 price target and Outperform rating on the shares.
October 1, 2015
07:05 EDTMDCOMedicines Company says BARDA exercises option on Carbavance pact
The Medicines Company announced that Rempex Pharmaceuticals, a wholly owned subsidiary, has been awarded the next option on a contract by the Biomedical Advanced Research and Development Authority, or BARDA, to support the development of CARBAVANCE. CARBAVANCE is the combination of a carbapenem antibiotic with a novel beta-lactamase inhibitor that is targeted for treatment of multi-drug resistant gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae. The cost-share contract with BARDA was initiated in 2014 and extends over 5 years. The award of this third option brings the total commitment from BARDA to $53.8M. If all options are exercised in the contract, it would bring the total value of the award to approximately $90M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use